These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31228256)

  • 1. Mammalian target of rapamycin (mTOR) inhibitors and skin cancer risk in nonrenal solid organ transplant recipients: systematic review and meta-analysis.
    Phan K; Moloney FJ; Hogarty DT; Lenane P; McColl D; Yazdabadi A
    Int J Dermatol; 2020 Jan; 59(1):91-98. PubMed ID: 31228256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
    Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
    Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
    Opelz G; Unterrainer C; Süsal C; Döhler B
    Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of nonmelanoma skin cancer in renal transplant recipients: A systematic review and meta-analysis.
    Matinfar M; Shahidi S; Feizi A
    J Res Med Sci; 2018; 23():14. PubMed ID: 29531566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmelanoma Skin Cancer Frequency and Risk Factors in Australian Heart and Lung Transplant Recipients.
    De Rosa N; Paddon VL; Liu Z; Glanville AR; Parsi K
    JAMA Dermatol; 2019 Jun; 155(6):716-719. PubMed ID: 30865218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of new immunosuppressive drugs in nonmelanoma skin cancer in renal transplant recipients.
    Bernat-García J; Morales Suárez-Varela M; Vilata-Corell JJ; Marquina-Vila A; Pallardo L; Crespo J
    Actas Dermosifiliogr; 2014 Dec; 105(10):940-6. PubMed ID: 25062648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients.
    Gluck M; Hodak E; Davidovici B
    Dermatol Ther; 2022 Aug; 35(8):e15649. PubMed ID: 35716099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review.
    Olszewska B; Imko-Walczuk B; Dębska-Ślizień A
    Postepy Dermatol Alergol; 2023 Apr; 40(2):187-193. PubMed ID: 37312910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periocular Skin Cancer in Solid Organ Transplant Recipients.
    Perry JD; Polito SC; Chundury RV; Singh AD; Fritz MA; Vidimos AT; Gastman BR; Koyfman SA
    Ophthalmology; 2016 Jan; 123(1):203-8. PubMed ID: 26520170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of heart transplant immunosuppressants and nonmelanoma skin cancer.
    Eckembrecher DG; Eckembrecher FJ; Camacho I; Shah H; Dave Y; Patel S; Nouri K
    Arch Dermatol Res; 2023 Nov; 315(9):2491-2503. PubMed ID: 37256379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
    Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
    J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials.
    Pengel LH; Liu LQ; Morris PJ
    Transpl Int; 2011 Dec; 24(12):1216-30. PubMed ID: 21955006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
    Grigg SE; Sarri GL; Gow PJ; Yeomans ND
    Aliment Pharmacol Ther; 2019 May; 49(10):1260-1273. PubMed ID: 30989721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial skin cancers after kidney transplantation: a retrospective single-centre study of 376 recipients.
    Kaufmann RA; Oberholzer PA; Cazzaniga S; Hunger RE
    Eur J Dermatol; 2016 Jun; 26(3):265-70. PubMed ID: 26985913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer and mTOR Inhibitors in Transplant Recipients.
    de Fijter JW
    Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Sirolimus Use With Risk for Skin Cancer in a Mixed-Organ Cohort of Solid-Organ Transplant Recipients With a History of Cancer.
    Karia PS; Azzi JR; Heher EC; Hills VM; Schmults CD
    JAMA Dermatol; 2016 May; 152(5):533-40. PubMed ID: 26792250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM; Kushwaha SS
    Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Risk of Internal Malignancy Following a Prior Diagnosis of Non-Melanoma Skin Cancer in Solid Organ Transplant Recipients.
    Gal N; Didkovsky E; Hodak E; Davidovici BB
    Isr Med Assoc J; 2022 Apr; 24(4):219-224. PubMed ID: 35415979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
    de Fijter JW
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.